Vanda Pharmaceuticals | VNDA - Loan Capital


Vanda Pharmaceuticals reported $3.15M in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 542.22M 1.25M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 603M 7M Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Takeda JPY 4.37T 99.51B Mar/2026
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Veracyte USD 0 0 Mar/2025